Novel dual inhibitors of nuclear factor-kappa B (NF-κB) and cyclooxygenase-2 (COX-2): Synthesis, in vitro anticancer activity and stability studies of lantadene-non steroidal anti-inflammatory drug (NSAID) conjugates

Current Topics in Medicinal Chemistry

Volumn 14, Issue 8, 2014, Pages 991-1004

  Suthar, Sharad Kumar ^a   Sharma, Neetika ^b   Lee, Hong Boon ^c   Nongalleima, Khumukcham ^d   Sharma, Manu ^a  

^a JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY   (India)

^b Bahra University   (India)

^c Drug Discovery Laboratory   (Malaysia)

^d INSTITUTE OF BIORESOURCES AND SUSTAINABLE DEVELOPMENT   (India)

Author keywords

Cyclooxygenase 2; Inhibitor of nuclear factor kappa B kinase ; Lantadene non steroidal anti inflammatory drug conjugates; Nuclear factor kappa B; Prodrugs

Indexed keywords

(3 BETA) (2 (2 (2,6 DICHLOROPHENYLAMINO)PHENYL)ACETOYLOXY) 22 BETA ANGELOYLOXY OLEAN 12 EN 28 OIC ACID; (3 BETA) (2 (2 (2,6 DICHLOROPHENYLAMINO)PHENYL)ACETOYLOXY) 22 BETA SENECIOYLOYLOXY OLEAN 12 EN 28 OIC ACID; (3 BETA) (2 (3 BENZOYLPHENYL)PROPANOYLOXY) 22 BETA ANGELOYLOXY OLEAN 12 EN 28 OIC ACID; (3 BETA) (2 (3 BENZOYLPHENYL)PROPANOYLOXY) 22 BETA SENECIOYLOXY OLEAN 12 EN 28 OIC ACID; (3 BETA) (2 (4 ISOBUTYLPHENYL)PROPANOYLOXY) 22 BETA ANGELOYLOXY OLEAN 12 EN 28 OIC ACID; (3 BETA) (2 (4 ISOBUTYLPHENYL)PROPANOYLOXY) 22 BETA SENECIOYLOXY OLEAN 12 EN 28 OIC ACID; (3 BETA) (2 ACETOXYBENZOYLOXY) 22 BETA ANGELOYLOXY OLEAN 12 EN 28 OIC ACID; (3 BETA) (2 ACETOXYBENZOYLOXY) 22 BETA SENECIOYLOXY OLEAN 12 EN 28 OIC ACID; 22 BETA (2 (2 (2,6 DICHLOROPHENYLAMINO)PHENYL)ACETOYLOXY) 3 OXO OLEAN 12 EN 28 OIC ACID; 22 BETA (2 ACETOXYBENZOYLOXY) 3 OXO OLEAN 12 EN 28 OIC ACID; 22 BETA 2 (3 BENZOYLPHENYL) PROPANOYLOXY) 3 OXO OLEAN 12 EN 28 OIC ACID; 22 BETA 2 (4 ISOBUTYLPHENYL) PROPANOYLOXY) 3 OXO OLEAN 12 EN 28 OIC ACID; 22 BETA 2 (6 METHOXYNAPHTHALEN 2 YL) PROPANOYL OXY) 3 OXO OLEAN 12 EN 28 OIC ACID; 22 BETA ANGELOYLOXY 3 OXO OLEAN 12 EN 28 OIC ACID; 22 BETA HYDROXY 3 OXO OLEAN 12 EN 28 OIC ACID; 22 BETA SENECIOYLOXY 3 OXO OLEAN 12 EN 28 OIC ACID; 3 BETA 2 (6 METHOXYNAPHTHALEN 2 YL)PROPANOYLOXY) 22 ANGELOYLOXY OLEAN 12 EN 28 OIC ACID; 3 BETA HYDROXY 22 BETA ANGELOYLOXY OLEAN 12 EN 28 OIC ACID; 3 BETA HYDROXY 22 BETA SENECIOYLOXY OLEAN 12 EN 28 OIC ACID; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LANTADENE; LANTADENE A; LANTADENE B; LANTANA CAMARA EXTRACT; NONSTEROID ANTIINFLAMMATORY AGENT; PLANT MEDICINAL PRODUCT; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; OLEANOLIC ACID; PLANT EXTRACT; PRODRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CONJUGATE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG ISOLATION; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACTION; HUMAN; HUMAN CELL; IC 50; LANTANA CAMARA; LUNG CANCER; MELTING POINT; PROTEIN PHOSPHORYLATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; CRYSTALLIZATION; LANTANA; PH; TUMOR CELL LINE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CRYSTALLIZATION; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; HYDROGEN-ION CONCENTRATION; LANTANA; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NF-KAPPA B; OLEANOLIC ACID; PLANT EXTRACTS; PRODRUGS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903707006     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666140324120503     Document Type: Article

References (25)

1. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357, 539-545.
2. Perwez Hussain, S.; Harris, C.C. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer, 2007, 121, 2373-2380.
3. Pikarsky, E.; Porat, R.M.; Stein, I.; Abramovitch, R.; Amit, S.; Kasem, S.; Gutkovich-Pyest, E.; Urieli-Shoval, S.; Galun, E.; Ben-Neriah, Y. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature, 2004, 431, 461-466.
4. Li, F.; Sethi, G. Targeting transcription factor NF-kappaB to over-come chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta, 2010, 1805, 167-180.
5. Aggarwal, B.B.; Shishodia, S.; Sandur, S.K.; Pandey, M.K.; Sethi, G. Inflammation and cancer: how hot is the link? Biochem. Pharmacol, 2006, 72, 1605-1621.
6. Aung, H.T.; Schroder, K.; Himes, S.R.; Brion, K.; van Zuylen, W.; Trieu, A.; Suzuki, H.; Hayashizaki, Y.; Hume, D.A.; Sweet, M.J.; Ravasi, T. LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. FASEB J., 2006, 20, 1315-1327.
7. Surh, Y.J.; Chun, K.S.; Cha, H.H.; Han, S.S.; Keum, Y.S.; Park, K.K.; Lee, S.S. Molecular mechanisms underlying chemopreven-tive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-κB activation. Mutat. Res., 2001, 480-481, 243-268.
8. Rao, C.V.; Reddy, B.S.; NSAIDs and chemoprevention. Curr. Cancer Drug Targets, 2004, 4, 29-42.
9. Cha, Y.I.; DuBois, R.N. NSAIDs and cancer prevention: targets downstream of COX-2. Annu. Rev. Med., 2007, 58, 239-252
10. Kaur, J.; Sharma, M.; Sharma, P.D.; Bansal, M.P. Chemopreventive activity of lantadenes on two-stage carcinogenesis model in Swiss albino mice: AP-1 (c-jun), NF kB (p65) and p55 expression by ELISA and immunohistochemical localization. Mol. Cell. Biochem., 2008, 314, 1-8.
11. Kaur, J.; Sharma, M.; Sharma, P.D.; Bansal, M.P. Antitumor activity of Lantadenes in DMBA/TPA induced skin tumors in mice: Expression of transcription factors. Am. J. Biomed. Sci., 2010, 2, 79-90.
12. Sharma, M.; Sharma, P.D.; Bansal, M.P.; Singh, J. Lantadene A-induced apoptosis in human leukemia HL-60 cells. Ind. J. Pharmacol, 2007, 39, 140-144.
13. Sharma, M.; Sharma, P.D.; Bansal, M.P. Lantadenes and their esters as potential antitumor agents. J. Nat. Prod., 2008, 71, 1222-1227.
14. Tailor, N.K.; Lee, H.B.; Sharma, M. Synthesis and in vitro anticancer studies of novel C-2 arylidene congeners of lantadenes. Eur. J. Med. Chem., 2013, 64, 285-291.
15. Tailor, N.K.; Jaiswal, V.; Lan, S.S.; Lee, H.B.; Sharma, M. Synthesis, selective cancer cytotoxicity and mechanistic studies of novel analogs of lantadenes. Anticancer Agents Med. Chem., 2013, 13, 957-966.
16. Tailor, N.K.; Lee, H.B.; Sharma, M. Effective melanoma inhibition by synthetic pentacyclic triterpenoid 2-(3-phenylprop-2-en-1-ylidene)-22p-hydroxy-3-oxoolean-12-en-28-oic acid: an in vitro and in vivo study. J. Environ. Pathol. Toxicol. Oncol, 2013, 32, 59-72.
17. Heynekamp, J.J.; Weber, W.M.; Hunsaker, L.A.; Gonzales, A.M.; Orlando, R.A.; Deck, L.M.; Jagt, D.L. Substituted trans-stilbenes, including analogues of the natural product resveratrol, inhibit the human tumor necrosis factor alpha-induced activation of transcription factor nuclear factor kappaB. J. Med. Chem., 2006, 49, 7182-7189.
18. Lorenzo, P.; Alvarez, R.; Ortiz, M. A.; Alvarez, S.; Piedrafita, F. J.; de Lera, A. R. Inhibition of IkappaB kinase-beta and anticancer activities of novel chalcone adamantyl arotinoids. J. Med. Chem., 2008, 51, 5431-5440.
19. Waffo-Teguo, P.; Lee, D.; Cuendet, M.; Mérillon, J.; Pezzuto, J.M.; Kinghorn, A.D. Two new stilbene dimer glucosides from grape (Vi-tis vinifera) cell cultures. J. Nat. Prod., 2001, 64, 136-138.
20. Schmid, J.A.; Birbach, A. IkappaB kinase beta (IKKbeta/IKK2/ IKBKB), a key molecule in signaling to the transcription factor NF-kappaB. Cytokine Growth Factor Rev., 2008, 19, 157-165.
21. Ballaz, S.; Mulshine, J.L. The potential contributions of chronic inflammation to lung carcinogenesis. Clin. Lung Cancer, 2003, 5, 46-62.
22. Blobaum, A.L.; Marnett, L.J. Structural and functional basis of cyclooxygenase inhibition. J. Med. Chem., 2007, 50, 1425-1441.
23. Xu, G.; Lo, Y.C.; Li, Q.; Napolitano, G.; Wu, X.; Jiang, X.; Dreano, M.; Karin, M.; Wu, H. Crystal structure of inhibitor of kB kinase p. Nature, 2011, 472, 325-330.
24. Kalia, M.; Kukol, A. Structure and dynamics of the kinase IKK-p -A key regulator of the NF-kappa B transcription factor. J. Struct. Biol, 2011, 176, 133-142.
25. Mercurio, F.; Zhu, H.; Murray, B.W.; Shevchenko, A.; Bennett, B.L.; Li, J.; Young, D.B.; Barbosa, M.; Mann, M.; Manning, A.; Rao, A. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science, 1997, 278, 860-866.